News
Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.
Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...
Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to ...
Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...
But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...
Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...
Novo Nordisk said on Tuesday it was working with telehealth firms Hims & Hers , Ro and LifeMD to sell Wegovy, as it looks to ...
The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...
It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback